Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cervical Carcinoma: early-phase trial registry
9 of 26 indexed Cervical Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #627 of 28,707 conditions by registered trial count.
26 US clinical trials · 9 currently recruiting · #627 of 28,707 conditions by registered trial count
Cervical Carcinoma: 26 US clinical trials tracked, 9 recruiting.
Cervical Carcinoma is the subject of 26 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Ohio State University Comprehensive Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition cervical-carcinoma
OPEN 9 | RECR 35% | LATE 0 | EARLY 12 | RANK #627 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Surgical Site Infection (35% recruiting · 26 trials)
Cervical Carcinoma lists 9 open slots (35% of 26 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cervical Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cervical Carcinoma is recruiting below its size-band peers.
9 of 26 indexed trials (34.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Cervical Carcinoma research.
Ohio State University Comprehensive Cancer Center accounts for 5 of 26 trials (19.2%). 16 distinct sponsors appear on at least one study for this condition label.
-
Typical Cervical Carcinoma enrolment sits around 130 participants.
Median target enrolment is 130 among the 26 trials that report a genuine target (sentinel values excluded). 12 of those (46.2%) plan for fewer than 100 participants.
-
Cervical Carcinoma research is mostly interventional.
24 interventional and 2 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
26 total, page 1 of 1
The Ohio State University (OSU) SCREEN Community Program
Ohio State University Comprehensive Cancer Center
NCT06666192
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
National Cancer Institute (NCI)
NCT06498661
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
National Cancer Institute (NCI)
NCT07281430
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
Mayo Clinic
NCT04567771
HPV Vaccine, Imiquimod, and Metformin Combination Trial
Baylor College of Medicine
NCT06686043
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Emory University
NCT06492070
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
NCT07118176
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT07285044
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Ohio State University Comprehensive Cancer Center
NCT07407647
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
NCT02465060
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)
National Cancer Institute (NCI)
NCT06611553
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)
National Cancer Institute (NCI)
NCT06611540
I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination
Ohio State University Comprehensive Cancer Center
NCT04452526
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Xencor
NCT05032040
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio
NCT07038369
Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy
Ohio State University Comprehensive Cancer Center
NCT04713618
Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer
M.D. Anderson Cancer Center
NCT00791635
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Jonsson Comprehensive Cancer Center
NCT04459273
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
University of Utah
NCT05139368
Cervical Cancer Screening Intervention Among Korean American Women
Fox Chase Cancer Center
NCT02594826
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology
NCT03180294
Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma
Memorial Sloan Kettering Cancer Center
NCT00595725
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
Gynecologic Oncology Group
NCT00081263
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
Ohio State University Comprehensive Cancer Center
NCT03307044
Linguistically-Tailored Mobile Intervention for the Improvement of Follow Up for Abnormal Pap Test Results
Thomas Jefferson University
NCT04821297
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
NCT05795595
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Cervical Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cervical Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cervical Carcinoma page
26 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Cervical Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ohio State University Comprehensive Cancer Center sponsors the most Cervical Carcinoma trials on record, review their full trial history before evaluating a specific study. See Ohio State University Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cervical Carcinoma condition card totals 26 registered trials; most-linked intervention Questionnaire Administration; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.